ORCHARD
ORCHARD: Phase II Study of Osimertinib + Datopotamab Deruxtecan in Advanced EGFRm NSCLC After 1L Osimertinib

Released: April 10, 2025

Expiration: October 09, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: April 10, 2025

Expiration: October 09, 2025